How Stress and the HPA Axis Affect Established Cardiovascular Disease

The HPA Axis: A Survival System That Turns Harmful

The hypothalamic-pituitary-adrenal axis is the body's central stress-response circuit. When the hypothalamus detects threat, it releases corticotropin-releasing hormone (CRH), which triggers pituitary secretion of adrenocorticotropic hormone (ACTH), which drives adrenal cortisol output. In acute danger, this cascade is protective. In chronic psychological stress, it becomes a cardiovascular liability.

Patients with established cardiovascular disease (history of MI, stroke, peripheral arterial disease, or symptomatic coronary disease) already carry an inflammatory, prothrombotic milieu. Sustained HPA activation layers additional risk on top of damaged vasculature. Cortisol promotes visceral adiposity, insulin resistance, endothelial dysfunction, and upregulation of IL-6 and TNF-alpha [1]. A 2017 Lancet study by Tawakol et al. demonstrated that heightened resting amygdalar metabolic activity (a neural correlate of chronic stress) independently predicted cardiovascular events over a median 3.7-year follow-up, with bone marrow activation and arterial inflammation mediating the link [2]. The pathway runs from brain to bone marrow to artery wall. That specificity matters. It means stress is not a vague modifier of heart risk. It is a discrete, measurable biological driver with identifiable therapeutic targets.

Cortisol, Inflammation, and Plaque Instability

Elevated cortisol does not simply raise blood pressure. It reshapes the atherosclerotic plaque toward rupture.

Chronic hypercortisolism increases monocyte recruitment into the arterial intima, thins the fibrous cap through upregulated matrix metalloproteinases (MMP-2, MMP-9), and promotes a prothrombotic state via elevated plasminogen activator inhibitor-1 (PAI-1) [3]. The Multi-Ethnic Study of Atherosclerosis (MESA) found that participants in the highest quartile of urinary cortisol excretion had significantly greater coronary artery calcium progression over 2.4 years compared to those in the lowest quartile, after adjustment for traditional risk factors [4].

For patients who have already experienced an MI or stroke, this biology is not theoretical. The INTERHEART study (N=29,972 across 52 countries) identified psychosocial stress factors (work stress, financial stress, major life events, depression) as responsible for 32.5% of population-attributable risk for acute MI, a contribution comparable to dyslipidemia and smoking combined [5]. A Swedish registry study following 30,912 post-MI patients found that those with chronic work stress had a 65% higher risk of recurrent MACE (HR 1.65 to 95% CI 1.23 to 2.22) over 8 years [6].

The clinical implication is direct: in secondary prevention, stress is not a soft endpoint. It is a hard risk factor that warrants the same systematic attention as LDL-C or blood pressure.

Depression, Anxiety, and Shared HPA Pathophysiology

Roughly 20% of post-MI patients meet diagnostic criteria for major depressive disorder within the first year, and another 20% experience subclinical depressive symptoms [7]. Depression and chronic stress share a common neuroendocrine signature: blunted diurnal cortisol variation, elevated evening cortisol, impaired glucocorticoid receptor sensitivity, and increased sympathetic nervous system tone.

The ENRICHD trial (N=2,481) demonstrated that depression after MI independently predicted recurrent cardiac events (HR 1.50 to 95% CI 1.14 to 1.98) after adjustment for disease severity [8]. While the cognitive-behavioral therapy (CBT) intervention in ENRICHD improved depression scores, it did not significantly reduce reinfarction or mortality, a finding that prompted a shift toward integrated pharmacologic and behavioral approaches.

Selective serotonin reuptake inhibitors (SSRIs) have shown cardiovascular safety in post-MI populations. The SADHART trial established sertraline's safety and modest efficacy for depression after acute coronary syndrome [9]. SSRIs also carry mild antiplatelet effects that may offer secondary benefit, though this should not drive prescribing decisions. Screening for depression and anxiety should be routine in every post-MI or post-stroke follow-up visit. The AHA recommends the Patient Health Questionnaire-2 (PHQ-2) as a minimum screen, escalating to the PHQ-9 when positive [7].

Measuring HPA Dysregulation in CVD Patients

Clinicians have several tools for quantifying cortisol burden, each with practical tradeoffs.

Salivary cortisol collected at waking and bedtime over two consecutive days provides the diurnal cortisol slope. A flattened slope (high evening cortisol relative to morning) is the pattern most consistently linked to adverse cardiovascular outcomes. The Whitehall II cohort study (N=4,047) demonstrated that participants with flattened diurnal cortisol slopes had a 36% higher incidence of cardiovascular mortality over 14 years [10].

Hair cortisol concentration (HCC) captures cumulative cortisol exposure over one to three months from a small posterior vertex sample. A meta-analysis of 16 studies found that HCC was significantly higher in individuals with acute MI compared to healthy controls (pooled SMD 0.75 to 95% CI 0.45 to 1.05) [11]. HCC eliminates the day-to-day variability that limits single-timepoint blood draws.

24-hour urinary free cortisol remains standard for ruling out Cushing syndrome but is less practical for population-level cardiovascular risk stratification. For most secondary prevention patients, a combination of standardized psychosocial screening (PHQ-9, Perceived Stress Scale) and one objective cortisol measure (salivary slope or HCC) offers a practical, evidence-grounded approach.

Exercise: The Strongest Non-Pharmacologic HPA Modulator

Regular aerobic exercise recalibrates HPA axis sensitivity in a dose-dependent fashion. Trained individuals show lower cortisol responses to both physical and psychosocial stressors compared to sedentary controls [12].

For patients with established CVD, the evidence is unambiguous. A Cochrane review of 63 trials (N=14,486) of exercise-based cardiac rehabilitation found a 27% reduction in cardiovascular mortality (RR 0.73 to 95% CI 0.54 to 0.98) and a 13% reduction in all-cause mortality (RR 0.87 to 95% CI 0.75 to 0.99) [13]. The 2019 ESC Guidelines for Chronic Coronary Syndromes assign a Class I, Level A recommendation to exercise-based cardiac rehabilitation for all patients with established CVD [14].

The minimum effective dose aligns with general population guidelines: 150 minutes per week of moderate-intensity activity or 75 minutes of vigorous activity, accumulated in bouts of at least 10 minutes. Resistance training on two or more days per week adds independent benefit. For patients with post-MI anxiety about exertion, supervised cardiac rehab provides both the physiologic stimulus and the psychological reassurance needed to build exercise tolerance.

High-intensity interval training (HIIT) protocols have shown superior improvements in VO2max compared to moderate continuous training in stable coronary artery disease patients in the SAINTEX-CAD trial, without increased adverse events [15]. The cortisol-lowering benefit of exercise plateaus at moderate volumes; overtraining paradoxically elevates cortisol and should be avoided in this population.

Structured Stress-Reduction Programs

Mindfulness-based stress reduction (MBSR), originally developed at the University of Massachusetts Medical Center, involves 8 weeks of guided meditation, body scanning, and gentle yoga in 2.5-hour weekly group sessions plus daily home practice. A systematic review and meta-analysis of 45 RCTs found that MBSR reduced salivary cortisol by a standardized mean difference of 0.34 (95% CI 0.19 to 0.49), corresponding to roughly a 15 to 25% reduction from baseline [16].

In cardiac populations specifically, the MHART-2 trial randomized 302 post-MI patients to an 8-week mindfulness intervention versus usual care and found significant reductions in perceived stress and anxiety scores, though the trial was not powered for MACE endpoints [17]. Transcendental Meditation (TM) has a slightly larger evidence base in CVD. A randomized trial of 201 Black adults with coronary artery disease found that TM practice over a median 5.4 years reduced the composite endpoint of all-cause mortality, MI, and stroke by 48% (HR 0.52 to 95% CI 0.29 to 0.92), with reductions in systolic blood pressure and anger scores [18].

The AHA issued a Class IIa recommendation (moderate evidence) for meditation as an adjunct to guideline-directed secondary prevention in a 2017 scientific statement [19]. Cognitive-behavioral stress management (CBSM) is another structured option. The SUPRIM trial (N=362) of CBT-based stress management in post-MI or post-CABG patients demonstrated a 41% reduction in recurrent cardiovascular events (HR 0.59 to 95% CI 0.42 to 0.83) and a 45% reduction in recurrent MI (HR 0.55 to 95% CI 0.36 to 0.85) over a median 94 months [20].

These are not wellness suggestions. They are interventions with randomized trial data, effect sizes, and confidence intervals.

Pharmacologic Strategies That Modulate the Stress-CVD Axis

Standard secondary prevention medications address components of the stress-CVD axis even when prescribed for other indications. Beta-blockers reduce sympathetic overdrive, lower resting heart rate, and attenuate catecholamine surges during stress. ACE inhibitors and ARBs reduce angiotensin II-mediated inflammation and have been associated with lower depression incidence in large observational studies [21].

The SELECT trial (N=17,604) established that semaglutide 2.4 mg once weekly reduced MACE by 20% (HR 0.80 to 95% CI 0.72 to 0.90) in adults with overweight or obesity and established CVD but without diabetes [22]. While the primary mechanism involves weight reduction, improved insulin sensitivity, and direct anti-inflammatory effects, the metabolic improvements also address cortisol-driven visceral adiposity and insulin resistance, two central features of HPA dysregulation.

Statins exert pleiotropic anti-inflammatory effects beyond LDL lowering, reducing hsCRP and stabilizing plaques through mechanisms that partially counteract cortisol-driven matrix metalloproteinase activation [23]. These pharmacologic strategies work best when layered onto the behavioral interventions described above. Medication alone does not normalize a chronically activated HPA axis. Exercise, structured stress reduction, adequate sleep (seven to nine hours), and treatment of comorbid depression form the foundation.

Building a Secondary Prevention Plan That Addresses Stress

The 2019 ESC Guidelines recommend a multicomponent cardiac rehabilitation model that includes exercise training, psychosocial management, and risk factor education [14]. In practice, stress management is often deprioritized relative to lipid targets and blood pressure goals. A complete secondary prevention stress-management approach includes five components.

First, screen every patient at each visit using the PHQ-2 and a one-item stress question ("On a scale of 1 to 10, how stressed have you felt in the past month?"). Second, refer all post-MI and post-stroke patients to exercise-based cardiac rehabilitation (participation rates remain below 25% in the US, a major care gap) [24]. Third, offer structured stress-reduction programs (MBSR, CBT, or TM) as adjunctive therapy, particularly for patients scoring high on perceived stress or screening positive for depression/anxiety. Fourth, optimize pharmacotherapy with attention to medications that address both cardiovascular risk and stress-axis physiology (beta-blockers, ACE inhibitors, SSRIs where indicated, GLP-1 receptor agonists where eligible). Fifth, address sleep. Short sleep duration (<6 hours) independently predicts elevated morning cortisol and increased MACE risk; the AHA added sleep to its Life's Essential 8 framework in 2022 [25].

Dr. Amit Khera, Professor of Medicine at UT Southwestern, has stated: "We have decades of data showing that psychosocial stress is as strong a risk factor as hypertension or smoking in secondary prevention patients. The challenge is not whether to address it, but building health systems that do so consistently."

Dr. Tara Narula, Associate Director of the Cardiac Care Unit at Lenox Hill Hospital, has noted: "Patients who complete cardiac rehab with an integrated stress-management component have measurably lower cortisol levels and fewer rehospitalizations. We need to stop treating stress as optional in cardiology."

The American Heart Association's 2021 scientific statement on psychological health and cardiovascular disease concluded that "the totality of evidence supports a causal relationship between psychological health and CVD risk" and recommended integrating psychological screening and treatment into routine cardiovascular care [26].

Cardiac rehabilitation enrollment is the single most impactful referral a clinician can make for a post-MI patient's stress biology. The number needed to treat (NNT) for cardiac rehab to prevent one cardiovascular death over five years is 37 [13].